LIFECORE BIOMEDICAL, INC. Sale of Stock, Consideration Received on Transaction
LIFECORE BIOMEDICAL, INC. (LFCR) had Sale of Stock, Consideration Received on Transaction of $24.30 million as of 2024-10-03, per its 10-KT filed 2026-03-16.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-03-16
- 2024-10-03: Sale of Stock, Consideration Received on Transaction $24.30M.
| Period end | Sale of Stock, Consideration Received on Transaction |
|---|---|
| 2024-10-03 | $24.30M 10-KT · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |